fashion -WSS

fashion

author：fashion 2025-08-25 07:26:07 - browse：7427

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Covid's long

WSS

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Virtual Event: March of the Biosimilars

Virtual Event: March of the Biosimilars

Physicians and social media: If you see something, say something?

Asbestos, a deadly carcinogen, banned by EPA

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Continuity nursing helped my family in our darkest PICU moments

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Activists slam private health insurers over coverage restrictions

Physicians and social media: If you see something, say something?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Timeline: Special counsel's investigation into Trump's handling of classified documents

New air purifier tech could be key to improving indoor air quality

Physicians and social media: If you see something, say something?

BioMarin wins approval for gene therapy to treat hemophilia A

Novo acquires Inversago for up to $1 billion

focus

Creating egg and sperm cells from stem cells raises ethical issues

An innovative path out of biotech’s “valley of death”

The perfect storm of weather conditions that led to the devastating wildfires in Maui

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Newly revealed memo details efforts to keep Trump in power following election loss

Health AI adoption puts security, privacy startups on investors' radar

focus

hotspot

focus

knowledge